Objective To investigate the clinical efficacy of nimotuzumab combined with gemcitabine in the treatment of locally advanced or metastatic pancreatic cancer and its effects on serum tumor markers, inflammatory cytokines and the expression of cancer tissue-related proteins. Methods A total of 86 patients with locally advanced or metastatic pancreatic cancer admitted to the First Affiliated Hospital of Henan University from January 2022 to July 2025 were selected, and divided into a control group and an observation group using a random number table method, with 43 cases in each group. The control group received gemcitabine treatment, while the observation group received additional nimotuzumab on the basis of the control group; both groups were treated continuously for 3 months. The clinical efficacy, the serum tumor marker levels, the serum inflammatory cytokine levels, the expression levels of tumor-related proteins in cancer tissue and the Ki-67 proliferation index, and the total incidence of adverse reactions were compared between the two groups. Results The disease control rate (DCR) in the observation group was higher than that in the control group (93.02% vs. 72.09%, P=0.011), but there was no statistically significant difference in the objective response rate between the two groups (67.44% vs. 51.16%, P=0.124). Before treatment, there were no statistically significant differences in the serum tumor markers, serum inflammatory cytokines, the expression levels of tumor-related proteins in cancer tissue, or the Ki-67 proliferation index between the two groups (all P>0.05). After 3 months of treatment, the observation group had lower levels of serum carbohydrate antigen (CA) 19-9, CA125, carcinoembryonic antigen, C-reactive protein, interleukin-6, and tumor necrosis factor-α, lower expression levels of epidermal growth factor receptor, human epidermal growth factor receptor 2, and β-catenin in cancer tissue, and a lower Ki-67 proliferation index than the control group, while the expression level of E-cadherin was higher than that in the control group (all P<0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group (6.98% vs. 25.58%, P=0.019). Conclusion Nimotuzumab combined with gemcitabine can improve the DCR in patients with locally advanced or metastatic pancreatic cancer, downregulate the levels of serum tumor markers and inflammatory cytokines, regulate the expression of proteins related to cancer cell proliferation and invasion in cancer tissue, and reduce adverse reactions.